Tuesday - April 28, 2026

Category Archives: Pharmaceuticals & Biotech

Dental Materials Market Set to Nearly Double to 82,881 Tons by 2033 as Aesthetic Dentistry and Material Innovation Redefine the Industry

dental materials market With nearly two-thirds of patients now preferring tooth-coloured restorations and global dental expenditures exceeding USD 140 billion annually, the shift toward premium, metal-free dental materials is no longer a trend — it is the new baseline. The … Continue reading →

Eczema Clinical Trial Pipeline Expands as 100+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Eczema Pipeline Insights 2026” Report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the Eczema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eczema pipeline therapeutics … Continue reading →

Type 1 Diabetes Treatment Pipeline Shows Strong Momentum as 85+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Type 1 Diabetes Pipeline Insight, 2026” report provides comprehensive insights about 85+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Chronic Myeloid Leukemia Pipeline Grows as 20+ Pharma Companies Advance Novel Blood Cancer Therapies, Finds DelveInsight | Renascience, Novartis Pharmaceuticals, Terns Pharmaceuticals

Chronic Myeloid Leukemia (CML) Pipeline Insights There are 20+ key companies, including Renascience, Novartis Pharmaceuticals, Terns Pharmaceuticals, Enliven Therapeutics, MacroGenics, Kartos Therapeutics, AOP Orphan Pharmaceuticals, and others, developing therapies for Chronic Myeloid Leukemia, with Renascience having its CML drug candidate … Continue reading →

Crohn’s Disease Pipeline Shows Strong Momentum as 90+ Pharma Companies Advance Novel Inflammatory Bowel Disease Therapies, Finds DelveInsight | AbbVie, Janssen, Merck, Takeda, Roche

Crohn’s Disease Pipeline Insight There are 90+ key companies, including AbbVie, Janssen, Merck, Takeda, Roche, AgomAb Therapeutics, Pfizer, Amgen, and others, developing therapies for Crohn’s disease, with companies like Janssen and Roche having candidates in the most advanced Phase III … Continue reading →

wAIHA Treatment Landscape: FDA Grants Priority Review to IMAAVY, Potential First Approved Therapy | Industry Insights on Market Impact, Competitive Landscape and Pipeline

Beyond wAIHA, nipocalimab is being studied in several other autoantibody-mediated diseases, including Sjögren’s disease, lupus, and generalized myasthenia gravis (where it is already approved). This multi-indication potential highlights the versatility of FcRn inhibition as a therapeutic platform for rare and … Continue reading →

Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Idiopathic Pulmonary Fibrosis Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Phenylketonuria Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Phenylketonuria Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Phenylketonuria pipeline landscape. It covers the Phenylketonuria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Phenylketonuria pipeline therapeutics … Continue reading →

Acute Respiratory Distress Syndrome Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Acute Respiratory Distress Syndrome Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Acute Respiratory Distress Syndrome pipeline landscape. It covers the Acute Respiratory Distress Syndrome pipeline drug profiles, including clinical and nonclinical … Continue reading →